All groups

Drug Delivery Partnerships

Email this page

This group is a drug delivery partnerships meeting place, focusing on bringing together professionals seeking the latest strategies, industry updates, and networking opportunities to help position your company for a successful partnership/collaboration.

Latest discussions

  • New Delivery Method to Assist Parkinson's Patients

    AbbVie's new Parkinson's drug DUOPA™ (carbidopa and levodopa) was recently approved by the FDA and is delivered straight into the patient's small intestine over a 16 hour period using an infusion pump and procedurally placed tube.

    "The FDA approval of Duopa is another significant milestone for AbbVie's pipeline," AbbVie Chief Scientific Officer Dr. Michael Severino said in a statement. "This advancement is important for patients with advanced Parkinson's disease and their care teams, as it provides a new therapeutic option to help manage motor symptoms."

    The oral delivery of levodopa/carbidopa is notorious for unpredictable absorption and this set off the search for new delivery methods - hence DUOPA and its percutaneous endoscopic gastrostomy procedure with jejunal extension, that delivers the drug into the small intestine by bypassing the stomach.

    However, this approval is coming off the heels of the FDA approval of Impax Laboratories' RYTARY which contains both immediate and extended release beads of carbidopa and levodopa. Learn more about RYTARY here:

    The drug delivery landscape is constantly evolving, don't get left behind! Join us at Drug Delivery Partnerships 2015 in Boca Raton, FL. Accelerate your path to market by leveraging new partnerships, breakthrough innovation and unique business models. Learn more:

    Last post Jan 15, 2015 by Ryan Geswell
  • Improve Cancer Therapies Through Nano-Reformulation

    At Drug Delivery Partnerships 2015 ( ) – Scott E. McNeil, PhD, Nanotechnology Characterization Lab (NCL), Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research will speak in a session titled “Improve Cancer Therapies Through Nano-Reformulation”

    Session Information:

    The Nanotechnology Characterization Laboratory’s (NCL) primary focus is the translation of nanotechnology formulations for cancer treatment. NCL has assisted nearly 100 different investigators and provided a range of characterization services (e.g. physicochemical, in vitro immunotoxicology, and in vivo animal studies) for over 300 different nanoformulations. Most cancer drugs are highly hydrophobic and have a multitude of dose-limiting toxic side effects. Nano-reformulation of these same drugs has proven potential to improve drug solubility, serve as a depot for controlled release, improve bioavailability and biodistribution, as well as reduce toxic side effects. This talk will provide a discussion of the benefits of nanotechnology reformulation to improve existing cancer therapies. Funded by NCI contract No. HHSN261200800001E.

    • Nanotechnology has been successful in helping dozens of drugs reach clinical trials and the commercial market.

    • Nanoformulation can improve efficacy and reduce side effects of existing treatments.

    • The NCL has a variety of reformulation and characterization options available to assist researchers in the advancement of their novel drugs or formulations.

    Continue reading:

    Last post Nov 18, 2014 by Ryan Geswell
  • What do you think are the main advantages of putting the control of the drug delivery devices into the hands of the patients?

    In today's Drug Delivery Partnerships post, we look at one way: subcutaneous (SC) administration .

    Last post Aug 19, 2014 by Jenny Pereira
  • Announcing Drug Delivery Partnerships Europe 2014!

    Drug Delivery Partnerships Europe 2014 will take place September 17-18 in Hamburg, Germany. We will be bringing you the latest cutting edge developments for crossing the blood brain barrier, novel systems for improving injectability, and technologies for addressing poorly soluble and poorly permeable compounds, and more!

    For more information and to download the brochure, visit the DDP Blog:

    Last post Jun 12, 2014 by Jenny Pereira
  • What is the one drug you think would profit the most from having an easier to administer oral dose?

    Aprecia Pharmaceuticals' new technology could make it possible. Find out more at today's Drug Delivery Partnerships Blog:

    Last post Jun 9, 2014 by Jenny Pereira